Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Multivariate Cox proportional hazard model analysis of pharmacokinetic parameters^{^a}
Hazard Ratio (95% CI)^{^a} P-value
Model 1: without MGMT methylation status
 Baseline median K^trans 1.19 (0.934–1.52) .158
 Posttreatment median K^trans 1.16 (0.958–1.40) .129
Model 2: with MGMT methylation status
 Baseline median K^trans 1.48 (1.12–1.93) .005
 Posttreatment median K^trans 1.01 (0.840–1.21) .935
 Presence of MGMT methylation 0.150 (0.0541–0.417) <.001
Model 3: by stepwise variable selection^{^b}
 Baseline median K^trans 1.49 (1.15–1.92) .003
 Posttreatment median K^trans 
 Percentage change of kurtosis K^trans 1.26 (0.951–1.66) .108
 Presence of MGMT methylation 0.143 (0.0541–0.375) <.001
↵a Hazard ratios for K^trans were adjusted for a unit change of 0.001 min⁻¹.
↵b A stepwise variable selection including baseline median K^trans, posttreatment median K^trans, the percentage change of kurtosis K^trans, and the methylation status of MGMT.

	Hazard Ratio (95% CI)^{^a}	P-value
Model 1: without MGMT methylation status
Baseline median K^trans	1.19 (0.934–1.52)	.158
Posttreatment median K^trans	1.16 (0.958–1.40)	.129
Model 2: with MGMT methylation status
Baseline median K^trans	1.48 (1.12–1.93)	.005
Posttreatment median K^trans	1.01 (0.840–1.21)	.935
Presence of MGMT methylation	0.150 (0.0541–0.417)	<.001
Model 3: by stepwise variable selection^{^b}
Baseline median K^trans	1.49 (1.15–1.92)	.003
Posttreatment median K^trans
Percentage change of kurtosis K^trans	1.26 (0.951–1.66)	.108
Presence of MGMT methylation	0.143 (0.0541–0.375)	<.001